scPharmaceuticals Inc
SCPH5.620USD
-0.010-0.18%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
299.49MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über scPharmaceuticals Inc Unternehmen
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Unternehmensinformationen
BörsenkürzelSCPH
Name des UnternehmensscPharmaceuticals Inc
IPO-datumNov 17, 2017
CEOMr. John H. Tucker
Anzahl der mitarbeiter162
WertpapierartOrdinary Share
GeschäftsjahresendeNov 17
Addresse25 Burlington Mall Road, Suite 203
StadtBURLINGTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl01803
Telefon16175170730
Websitehttps://www.scpharmaceuticals.com/
BörsenkürzelSCPH
IPO-datumNov 17, 2017
CEOMr. John H. Tucker
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John H. Tucker
Mr. John H. Tucker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
122.34K
-55.88%
Mr. Leonard D. Schaeffer
Mr. Leonard D. Schaeffer
Independent Director
Independent Director
111.90K
--
Ms. Rachael Nokes
Ms. Rachael Nokes
Chief Financial Officer
Chief Financial Officer
30.39K
-71.18%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Jack A. Khattar
Mr. Jack A. Khattar
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Klaus Veitinger, M.D., Ph.D.
Dr. Klaus Veitinger, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William T. Abraham, M.D.
Dr. William T. Abraham, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John H. Tucker
Mr. John H. Tucker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
122.34K
-55.88%
Mr. Leonard D. Schaeffer
Mr. Leonard D. Schaeffer
Independent Director
Independent Director
111.90K
--
Ms. Rachael Nokes
Ms. Rachael Nokes
Chief Financial Officer
Chief Financial Officer
30.39K
-71.18%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Sep 13
Aktualisiert: Sat, Sep 13
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
8.57%
Luther King Capital Management Corp.
6.60%
Lytton (Laurence W)
5.49%
AIGH Capital Management, LLC.
5.40%
Andere
62.65%
Aktionäre
Aktionäre
Anteil
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
8.57%
Luther King Capital Management Corp.
6.60%
Lytton (Laurence W)
5.49%
AIGH Capital Management, LLC.
5.40%
Andere
62.65%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
26.25%
Hedge Fund
19.70%
Private Equity
17.73%
Investment Advisor/Hedge Fund
10.47%
Individual Investor
5.98%
Research Firm
3.74%
Venture Capital
2.30%
Bank and Trust
0.14%
Insurance Company
0.02%
Andere
13.67%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
207
43.86M
83.06%
-9.87M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
2023Q2
160
30.81M
85.97%
-2.10M
2023Q1
135
26.76M
76.80%
-865.96K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
OrbiMed Advisors, LLC
6.06M
11.48%
--
--
Mar 31, 2025
Rubric Capital Management LP
4.78M
9.04%
--
--
Mar 31, 2025
Luther King Capital Management Corp.
3.12M
5.91%
+263.26K
+9.21%
Mar 31, 2025
Lytton (Laurence W)
2.94M
5.58%
+1.12M
+61.35%
Sep 30, 2024
AIGH Capital Management, LLC.
3.10M
5.86%
--
--
Mar 31, 2025
Lundbeckfond Invest
2.86M
5.42%
+2.86M
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.15M
4.08%
+43.64K
+2.07%
Mar 31, 2025
The Vanguard Group, Inc.
1.99M
3.77%
-115.70K
-5.49%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.65M
3.12%
-29.52K
-1.76%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.64%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.64%
iShares Micro-Cap ETF
Anteil0.04%
ProShares Ultra Nasdaq Biotechnology
Anteil0.03%
Invesco Nasdaq Biotechnology ETF
Anteil0.03%
Global X Russell 2000 ETF
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
